INVESTIGATING THE ROLE OF KISSPEPTIN IN BREAST CANCER: A STUDY ON KISSPEPTIN LEVELS AND THEIR CLINICAL SIGNIFICANCE
DOI:
https://doi.org/10.53555/3mz9km28Keywords:
Breast cancer, Kisspeptin, ELISA, Blood sample, Prognostic biomarkerAbstract
Background
Breast cancer remains a significant global health concern, necessitating continued research to uncover its molecular mechanisms and identify novel therapeutic targets. Kisspeptin, a peptide originally recognized for its role in reproductive physiology, has recently gained attention for its potential involvement in cancer progression. This study investigates the clinical significance of kisspeptin levels in breast cancer patients.
Methods
A total of 100 breast cancer patients were enrolled in the study. Blood samples were collected, and kisspeptin levels were quantified using Enzyme-Linked Immunosorbent Assay (ELISA). Associations between kisspeptin levels and clinicopathological parameters—including tumor stage, histological grade, hormone receptor status, and patient outcomes—were analyzed.
Results
Preliminary analysis revealed significant correlations between kisspeptin levels and key clinical parameters. Higher or lower kisspeptin expression was observed in relation to tumor progression and hormone receptor status (specific statistical outcomes to be included as available). These findings suggest a potential prognostic value of kisspeptin in breast cancer.
Conclusion
Kisspeptin shows promise as a prognostic biomarker and potential therapeutic target in breast cancer management. Understanding its role in breast cancer pathogenesis could enhance personalized treatment strategies. Further studies are needed to validate these findings and clarify the mechanistic role of kisspeptin in breast cancer.
References
1. Luo, Y., Hou, Z., Feng, G., Xiong, D., & Chen, J. (2024). CDCA2 promotes breast cancer progression by downregulating KISS1 expression. European Journal of Gynaecological Oncology, 45(2), 127-134.
2. Wu, H. M., Chen, L. H., Chiu, W. J., & Tsai, C. L. (2024). Kisspeptin Regulates Cell Invasion and Migration in Endometrial Cancer. Journal of the Endocrine Society, 8(3), bvae001.
3. Makri, A., Pissimissis, N., Lembessis, P., Polychronakos, C., & Koutsilieris, M. (2008). The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer treatment reviews, 34(8), 682-692.
4. Stathaki, M., Stamatiou, M. E., Magioris, G., Simantiris, S., Syrigos, N., Dourakis, S., ... & Armakolas, A. (2019). The role of kisspeptin system in cancer biology. Critical reviews in oncology/hematology, 142, 130-140.
5. Bhattacharya, M., & Babwah, A. V. (2015). Kisspeptin: beyond the brain. Endocrinology, 156(4), 1218-1227.
6. Lee, J. H., & Welch, D. R. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer research, 57(12), 2384-2387.
7. Singh, R., Bhatt, M. L. B., Singh, S. P., Kumar, V., Goel, M. M., Mishra, D. P., & Kumar, R. (2016). Evaluation of KiSS1 as a prognostic biomarker in North Indian breast cancer cases. Asian Pacific Journal of Cancer Prevention, 17(4), 1789-1795.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Population Therapeutics and Clinical Pharmacology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.